Aarti drugs ltd
Plot No. N – 198,
M.I.D.C., Tarapur, Village – Pamtembhi,
Taluka & Dist. Palghar – 401 506.
Part of the USD 500 million Aarti Group of Industries, Aarti Drugs Ltd (ADL) was established way back in in 1984.
Since its inception, the Company has established a strong presence in the Anti-diarrhea, Anti-inflammatory therapeutic groups. With its manufacturing facilities at Tarapur and Sarigam, the Company manufactures Vitamins, Anti-arthritis, Anti-fungal, Antibiotics, ACE inhibitors, besides its range in , anti-diabetic, anti-cholinergic, sedatives and anti-depressant drugs.
Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.
The manufacturing-units of ADL are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.
The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery
Formulation business have been launched to gain value addition over own API Based Formulations.
Objective to make presence feel in terms of form- ulations business among our esteem customers and capability to produce quality formulations.
Co- marketing tie ups with various company in the area of DCGI products under their brands on exclusive basis.
Third party export by using our API capabilities as well as technical competence in the areas of various dosage forms.
Registering own brand in unregulated market-focusing on API strength and converting into formulation /s under various dosage forms.
With the focus to build world-class capabilities, ADL has been successful in developing the state-of-the-art R & D Center at Turbhe near Mumbai, besides, it also have 2 In built supporting R & D Centers within our mfg. sites which all are well recognized by Department of Science and Industrial Research, Government of India , headed effectively by skilled & dedicated researchers who have successfully developed, around 30 new molecules within the past four years. Today, the Company, through its innovative and cost-effective process, is continuously developing new value added molecules.
The Strength of R & D team lies in the vast experience & knowledge they possess in the field of Chemistry / synthetic organic chemistry & testing instruments.
Starting from the process research within the labs, process optimization at kilo lab, Pilot Plant and trouble shooting during commercialization, R & D activities, synthesis, isolation, characterization of Related Substance, Reference Standards and Development of analytical methods form the main areas of work, of the Companys’ team of analytical development group.
With two decades of manufacturing experience behind, the Company has today transformed into multi-ton, multi-location GMP complaint with the state-of the art facilities. Strategically located at Tarapur (Maharashtra) and Sarigam (Gujarat), the manufacturing units are currently capable of making over 50 bulk actives, several key intermediates and Speciality chemicals.
With (a strength of) eight manufacturing locations in its portfolio , ADL today, has total reaction capacity in excess of 1000 KL, consisting of SS and GL reactors across its units, varying from 0.5 KL – 12 KL.
Manufacturing in accordance with GMP regulations norms, Pilot Plants, Process development labs, In – Process QC labs and dedicated product processing areas are common features across every plant.
Unit processes for milling, sieving, blending, micronising and packing area are well in place. As a part of the pre-approval processes, these facilities have been inspected and approved by large end users, customers, who are rated amongst the largest companies in the world.
Combining its expertise, capabilities and long term experience of multi-step synthesis and fractionations at high temperatures has provided ADL with an excellent position as a manufacturing partner. The capacity of these multi-purpose plant ranges from 1 up till 100’s of tons.
The Company has the capability and the flexibility to manage projects that range from grams to tons with system checks to ensure strict confidentially. ADL’s involvement can begin as early as the stabilization of process. The Company could contribute to the project in terms of its process fine-tuning on technical, cost or environmental factors.
A technically expert team is working closely with the customer, with well-defined time frame and milestones to comprehend customers requirement and translate them in to an efficient process. In most cases, the Company would be able to provide dedicated facilities, required for specific projects.
Pursuant to Sections 205A and 205C of the Companies Act, 1956, the Company is required to transfer the amount of dividend remained unclaimed for a period of seven years from the date of transfer to the Investor Education and Protection Fund (IEPF).
Ministry of Corporate Affairs has issued a Circular notifying the Rule “Investor Education and Protection Fund (Uploading of information regarding unpaid and unclaimed amounts lying with Companies) Rules, 2012”. As per this Rule, companies have to identify and upload details of unclaimed dividend on their website. Accordingly detailed information in respect of the relevant financial years is provided for the benefit of the Company’s Investors.
Krebs Biochemicals & Industries Limited
click above to visit
this company/ organization